Shares of ImmunoGen (NASDAQ: IMGN) closed down 10.6% on Thursday on no apparent news. The volatile biotech stock is, well, volatile. It's not exactly the first time we've seen a double-digit move on no news.
ImmunoGen's investors are in a wait mode, having fully enrolled the phase 3 Forward 1 clinical trial testing mirvetuximab as a monotherapy in platinum-resistant ovarian cancer. Data from the trial is expected next year. If positive, the data should be enough to gain regulatory approval for mirvetuximab.
Image source: Getty Images.
Between now and then, investors can expect some earlier-stage data for mirvetuximab. The phase 2 trial, dubbed Forward 2, will read out data for patients treated with mirvetuximab and Merck's (NYSE: MRK) Keytruda at the European Society for Medical Oncology meeting this month.
And in December, data for ImmunoGen's earlier-stage assets IMGN779 and IMGN632 is expected at the American Society of Hematology meeting. Both drugs are only in phase 1, but they give investors an idea of what could follow after mirvetuximab.
Long-term investors should ignore the daily gyrations in the stock price and focus on ImmunoGen's clinical trial data. Forward 1 is clearly the most important clinical trial to get mirvetuximab on the market, but other data later this year should tide investors over while they wait.
More From The Motley Fool
- 10 Best Stocks to Buy Today
- 3 Stocks That Are Absurdly Cheap Right Now
- 5 Warren Buffett Principles to Remember in a Volatile Stock Market
- The $16,728 Social Security Bonus You Cannot Afford to Miss
- The Must-Read Trump Quote on Social Security
- 10 Reasons Why I'm Selling All of My Apple Stock